Serum Institute’s Cervavac HPV Vaccine Earns WHO Prequalification
The World Health Organization has officially granted prequalification status to Cervavac, an indigenously manufactured quadrivalent human papillomavirus vaccine produced by the Serum Institute of India. This regulatory milestone unlocks international procurement channels, permitting United Nations agencies and global health organizations to distribute the prophylactic treatment across developing immunization programs.
WHO prequalification makes Cervavac eligible for procurement by United Nations agencies, opening avenues for its inclusion in national immunization programmes internationally.
Serum Institute of India CEO Adar Poonawalla publicly described WHO prequalification of Cervavac as an important step in strengthening the global response to HPV.
The WHO's official listing recorded Cervavac prequalification as effective September 25, 2026, representing the 32nd WHO prequalified biological achieved by Serum Institute of India.
The immunization formulation is engineered to neutralize four distinct viral strains, specifically human papillomavirus types 6, 11, 16, and 18. Medical guidelines authorize the administration of Cervavac to both female and male recipients spanning from nine through 26 years of age. Vaccination protocols require intramuscular delivery, with commercial presentations available in single-dose 0.5-milliliter vials as well as two-dose 1.0-milliliter containers.
Cervavac is available in single dose vial and multidose vial (2 doses) presentations.
Collaborative Development and Regulatory Background
Creation of the prophylactic agent involved an extensive multi-institutional partnership bridging domestic research bodies and international health foundations. The venture united the Serum Institute of India alongside the Department of Biotechnology and the Biotechnology Industry Research Assistance Council, working in tandem with the World Health Organization International Agency for Research on Cancer and the Gates Foundation.
Development of Cervavac was conducted collaboratively by Serum Institute of India, India's DBT, BIRAC, the Gates Foundation, and WHO-IARC.
Prior to clearing international regulatory hurdles, the vaccine secured domestic authorization from the Drugs Controller General of India. Clinical deployment targets the prevention of multiple malignancies, including cervical, vulvar, vaginal, and anal cancers in women and girls, alongside anal cancer in men and boys. Furthermore, the formulation addresses the prevention of genital warts within the designated age cohort.
Global Strategic Relevance
Adar Poonawalla, chief executive officer of the Serum Institute of India, noted that securing international validation marks a critical progression in expanding worldwide defenses against papillomavirus transmission. The decision creates pathways for nations to scale up preventive interventions against viral-associated health risks.
With this latest inclusion, the Pune-based manufacturer has accumulated 32 distinct prequalifications for biological products issued by the international health body. The regulatory endorsement removes significant barriers to international distribution, positioning the domestically engineered vaccine as a central tool in broader multilateral immunization campaigns.
What WHO prequalification changes
Prequalification is an important procurement and quality-assurance milestone for a vaccine. It helps eligible international buyers evaluate a product against WHO standards; it is not the same as a new vaccination recommendation for every person in every country. Cervical-cancer prevention still depends on vaccination coverage, age-appropriate schedules, access to screening and national programme decisions. Readers should distinguish global procurement eligibility from domestic regulatory approval and availability at a particular clinic. Price, supply agreements and rollout dates will determine how quickly this milestone reaches patients.